{"filings":[{"id":1370239,"accession_number":"0001213900-26-073998","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2026-07-01T12:05:36+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Allarity Therapeutics granted U.S. patent for stenoparib DRP companion diagnostic through April 2042","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["USPTO granted key U.S. patent covering stenoparib-specific Drug Response Predictor (DRP) companion diagnostic.","Patent term extends into April 2042, providing long-term exclusivity for stenoparib when used with the DRP test.","Patent covers methods to predict clinical benefit from stenoparib based on tumor gene-expression profiles and patient selection.","Allarity also has patent protection for stenoparib DRP in Europe and Australia into 2039."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1177357,"accession_number":"0001213900-26-070382","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2026-06-22T12:10:21+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity announces Trial-in-Progress poster for Phase 2 stenoparib at ESMO Gynaecological Cancers Congress 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Poster outlines Phase 2 trial of stenoparib (dual PARP/WNT inhibitor) for platinum-resistant ovarian cancer.","Presented by Principal Investigator Dr. Kathleen N. Moore, expert in advanced ovarian cancer.","No new clinical data reported; Trial-in-Progress design describes study rationale and design only.","Conference held June 17–19, 2026 in Copenhagen, Denmark; poster displayed June 18, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":808278,"accession_number":"0001213900-26-064278","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2026-06-02T21:10:31+00:00","items":["5.02","9.01"],"status":"ready","headline":"Allarity amends CEO Thomas Jensen's management agreement; increases severance, alters pay structure","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base compensation set at SEK 6,000,000 (80%) and US$163,043 (20%) annually; eliminates $100,000 signing bonus.","Termination for convenience: notice period increased from 15 to 30 days; now includes 12 months of Monthly Fee as severance.","Termination for Good Reason: now entitles consultant to Accrued Payments plus 12 months of Monthly Fee (replaces prior 9 months).","Annual bonus capped at 60% of Monthly Fees; performance metrics carry over if not updated by March 31 each year.","Adds Section 409A and 280G tax compliance provisions; extends non-solicitation period to 12 months post-termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96350,"accession_number":"0001213900-26-054019","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Allarity Therapeutics CEO to present at Precision Medicine Forum Europe 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Thomas Jensen will speak on May 11, 2026, in Stockholm, Sweden at Precision Medicine Forum Europe 2026.","Presentation will cover stenoparib (2X-121), a dual PARP and WNT pathway inhibitor, and the Stenoparib DRP biomarker.","Allarity is a Phase 2 clinical-stage company developing stenoparib for cancer; no new clinical data or financial results announced.","A corporate presentation furnished as Exhibit 99.1 will be used in investor meetings beginning May 11, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96349,"accession_number":"0001213900-26-052542","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity Therapeutics updates stenoparib manufacturing on track for Q3 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["API manufacturing campaign on track for completion no later than Q3 2026 at GMP-compliant CDMO.","All manufacturing payments completed; no additional cash outlays anticipated.","Supports potential pivotal trial in advanced ovarian cancer following FDA Fast Track designation.","Ongoing Phase 2 trial in advanced ovarian cancer continues enrolling under amended protocol.","Phase 2 trial of stenoparib + temozolomide for relapsed SCLC recruiting across multiple VA sites."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96348,"accession_number":"0001213900-26-048277","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity Therapeutics receives USPTO Notice of Allowance for stenoparib DRP companion diagnostic patent","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice of Allowance covers multiple claims for methods predicting clinical benefit and patient selection via gene expression.","Patent expected to be granted within three months; would provide exclusivity at least into 2039 for stenoparib with DRP test.","Allarity previously secured European and Australian patents for Stenoparib DRP; holds 18 granted patents for other drug-specific DRPs.","Patent applications for Stenoparib DRP remain pending in Canada, Japan, China, and India."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96347,"accession_number":"0001213900-26-046411","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity Therapeutics presents AACR posters on stenoparib for colorectal cancer and ovarian cancer survival","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Poster 2: stenoparib blocks WNT/β-catenin signaling and inhibits growth of colorectal cancer cell lines at clinically relevant concentrations.","Poster 1: Highest stenoparib DRP® scores are associated with enhanced overall survival in phase 2 ovarian cancer trial (NCT03878849).","CEO Thomas Jensen highlights stenoparib potential in colorectal cancer, a large area of unmet need in oncology.","DRP® companion diagnostic platform may identify patients most likely to achieve extended survival with stenoparib."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96346,"accession_number":"0001213900-26-038061","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allarity Therapeutics FY2025 net loss $11.2M, cash $14.7M, stenoparib Fast Track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss improved to $11.2M ($0.78/shr) from $25.1M ($15.65/shr) in 2024; first revenue of $320k.","Year-end cash $14.7M; extended runway with $20M non-convertible debt financing closed March 2026.","Stenoparib received FDA Fast Track for advanced ovarian cancer; new Phase 2 protocol implemented.","VA-funded Phase 2 combo trial (stenoparib+temozolomide) in SCLC opened at 11 VA sites; first patients dosed early 2026.","Jeff Ervin appointed CFO in July 2025 as part of leadership strengthening; DRP platform licensing initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110173,"accession_number":"0001213900-26-024952","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity closes $20M non-convertible debt with Streeterville; extends cash runway to mid-2028","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Closed $20M non-convertible debt financing with Streeterville Capital via two promissory notes: $10.93M and $10M.","Net proceeds extend cash runway into summer 2028; funds Phase 2 ovarian cancer trial and FDA preparation.","Proceeds also support pivotal trial prep, companion diagnostic strategy, and potential expansion into other WNT-driven tumors.","Stenoparib has shown durable clinical benefit; some patients on therapy >30 months in Phase 2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110172,"accession_number":"0001213900-26-024339","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Allarity Therapeutics obtains $20M debt financing from Streeterville Capital with $20.93M notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $10.93M A-1 Note (9% interest) and $10M secured B Note (5% interest) for $20M purchase price.","$900K OID and $30K expense included; maturity 18 months from March 2, 2026.","B Note secured by $10M deposit account and pledge of ALLR Holdings LLC; guaranteed by three subsidiaries.","Covenants restrict additional debt, variable-rate issuances, and asset encumbrances without lender consent.","Investor can redeem up to $250K/month starting 6 months after closing; trigger events allow 10%/5% balance increases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110171,"accession_number":"0001213900-26-018161","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity Therapeutics doses first patients in VA-funded Phase 2 trial of stenoparib + temozolomide for relapsed SCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patients dosed with stenoparib and temozolomide in Phase 2 trial for relapsed small cell lung cancer (SCLC).","Trial fully funded by U.S. Department of Veterans Affairs, enrolling at 11 VA medical centers nationwide.","Stenoparib is a dual PARP and WNT pathway inhibitor; prior PARP inhibitors limited by hematologic toxicity.","CEO cites fast enrollment and high unmet need; ~60-70% of SCLC patients present with extensive-stage disease.","Stenoparib crosses blood-brain barrier, relevant for SCLC brain metastases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110170,"accession_number":"0001213900-26-011826","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity opens Phase 2 trial of stenoparib + temozolomide in relapsed SCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment open at 11 VA sites for NCT06681220; trial fully funded by U.S. Department of Veterans Affairs.","Phase 2 evaluates stenoparib (dual PARP/WNT inhibitor) plus temozolomide in recurrent small cell lung cancer.","Study uses a blood-based biomarker to select patients most likely to benefit from the combination.","Stenoparib's favorable safety profile is cited as key rationale for combination with temozolomide.","Stenoparib crosses the blood-brain barrier, offering potential for brain metastases common in advanced SCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110169,"accession_number":"0001213900-26-009157","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Allarity Therapeutics enters $6M equity line of credit with Tumim Stone Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company may sell up to $6M of common stock at 95-97% of VWAP discount.","Commitment fee of $45,000 paid to investor upon execution.","Shares subject to Exchange Cap (19.99% of outstanding) unless stockholder waiver obtained.","Company must seek stockholder approval at next annual meeting to waive Exchange Cap.","Investor cannot own more than 4.99% (or 9.99% at its election) of outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126731,"accession_number":"0001213900-25-124935","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Allarity Therapeutics closes additional $250K private placement, issuing 255,103 shares at $0.98/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Additional Closing on Dec 23, 2025; 255,103 shares at $0.98/share for gross proceeds of ~$250,000.","Proceeds from the additional issuance will be used for general corporate purposes and working capital.","Shares were issued in a private placement under Section 4(a)(2) exemption, with restrictive legends."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126730,"accession_number":"0001213900-25-118989","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Allarity Therapeutics CFO Jeffrey Ervin moves to full-time; gets $367.7K salary, $160K RSUs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Jeffrey S. Ervin transitioned from part-time to full-time effective December 3, 2025 under new employment agreement.","Annual base salary set at $367,700; eligible for annual bonus up to 30% of base salary.","Granted restricted stock units valued at $160,000, vesting in equal installments over three years.","Severance of six months base salary if terminated without cause, for good reason, or in connection with change of control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143520,"accession_number":"0001213900-25-090872","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-09-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity Therapeutics: Phase 2 stenoparib shows median overall survival >25 months for platinum-resistant ovarian cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median overall survival (mOS) now exceeds 25 months, not yet formally reached, in ongoing Phase 2 trial.","Two patients remain on therapy >24 months; one with BRCA wild-type shows benefit, typically precluded by PARP inhibitors.","Data presented at AACR 2025 Ovarian Cancer Conference; FDA draft guidance supports OS as endpoint for approval.","Stenoparib shows less myelotoxicity vs earlier PARP inhibitors, relevant after 2022 market withdrawal of some PARP inhibitors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143519,"accession_number":"0001213900-25-090197","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Allarity Therapeutics raises ~$2.5M in private placement, with option for additional $7.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 1,562,500 shares at $1.60/sh and/or pre-funded warrants at $1.5999 for gross proceeds ~$2.5M.","Initial closing scheduled for Sept 23, 2025, subject to customary closing conditions.","Investor has 90-day option to purchase additional shares/warrants for up to $7.5M at then-current minimum price.","Shares and warrants issued in private placement under Section 4(a)(2); registration rights agreement filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143518,"accession_number":"0001213900-25-089680","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity CEO to present at Biomarkers & Precision Medicine 2025 in London on Oct 1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Thomas Jensen invited to present at Oxford Global conference on October 1, 2025.","Presentation title: 'A Gene Expression Based Biomarker For Predicting Response To Treatment With Stenoparib'.","Jensen will also be interviewed by Oxford Global's editorial team for their online portal.","Jensen available for one-on-one meetings during the conference to discuss business development.","Allarity is a Phase 2 clinical-stage company developing dual PARP/WNT inhibitor stenoparib."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143517,"accession_number":"0001213900-25-080923","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity receives FDA Fast Track for stenoparib in advanced ovarian cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Fast Track designation to stenoparib for advanced ovarian cancer on August 26, 2025.","Fast Track enables expedited development, potential accelerated/priority review and rolling review.","Company began Phase 2 enrollment in June 2025; several patients already dosed.","Prior Phase 2 data showed durable clinical benefit including patients on treatment >22 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143516,"accession_number":"0001213900-25-064456","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity Therapeutics announces DRP licensing and lab services deal with EU biotech","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-exclusive global license to selected DRP algorithms in breast cancer granted to an undisclosed EU-based biotech company.","Allarity will provide advanced transcriptome analysis services from its Denmark lab; purchase commitments secured for next year.","Company states the agreement is not expected to have a significant impact on its financial outlook.","CEO Thomas Jensen says deal validates DRP platform and offsets internal operating costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143515,"accession_number":"0001213900-25-061639","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Allarity Therapeutics CFO resigns; appoints Jeffrey Ervin as part-time CFO effective July 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Alexander Epshinsky resigned June 30, 2025; not due to any disagreement with the company.","Jeffrey S. Ervin appointed part-time CFO on July 1, 2025; annual base salary of $175,000.","Ervin previously served as fractional co-CFO of DDC Enterprise (NYSE: DDC) and chairman/CEO of IMAC Holdings (Nasdaq: BACK).","Ervin also serves as independent director of Cingulate, Inc. (Nasdaq: CING); holds MBA from Vanderbilt.","Severance: 6 months' base salary if terminated after Change-of-Control, subject to signed release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143514,"accession_number":"0001213900-25-060366","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity Therapeutics receives Australian patent acceptance for stenoparib DRP companion diagnostic","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["IP Australia accepted patent application covering 40 claims for DRP companion diagnostic specific to stenoparib.","Patent to be advertised June 26, 2025; three-month opposition period; grant expected within 20 working days if unopposed.","Company holds 18 granted drug-specific DRP patents, including 8 in US; European patent for stenoparib DRP previously secured.","Applications pending in US, Canada, Japan, China, and India."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161704,"accession_number":"0001437749-25-021482","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity dosed second patient in new Phase 2 stenoparib trial for advanced ovarian cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second patient dosed in new Phase 2 trial of stenoparib for advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer.","CEO Thomas Jensen cited strong investigator engagement and rapid enrollment pace.","Trial builds on prior Phase 2 data showing durable benefit and favorable tolerability with twice-daily dosing.","Stenoparib is a dual PARP and WNT pathway inhibitor; trial also advances DRP companion diagnostic.","Current platinum-resistant patients have limited treatment options; stenoparib aims to offer a better-tolerated alternative."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161703,"accession_number":"0001437749-25-020652","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Allarity shareholders reject equity plan increase and officer exculpation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Thomas H. Jensen re-elected as Class III director with 1,673,698 for, 265,465 withheld.","Ratification of Wolf & Company as auditor passed with 6,706,148 votes for.","Proposal to increase 2021 Plan shares from 717,941 to 3,415,068 failed (928,978 for vs 932,866 against).","Amendment to limit officer liability (Officer Exculpation) also did not pass (1,359,331 for vs 563,585 against).","Adjournment proposal approved 4,976,159 for, 1,924,694 against; quorum was 41% of outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161702,"accession_number":"0001437749-25-020081","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Allarity Therapeutics appoints Jesper Høiland to board, replacing Joseph Vazzano","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joseph Vazzano resigned as director effective June 30, 2025.","Jesper Høiland appointed director effective June 30, 2025; term expires at 2026 annual meeting.","Høiland joins Audit, Compensation, and Nominating & Governance Committees.","Høiland receives $50,000 annual retainer plus committee fees ($7,500/$5,000/$4,000).","Høiland had served as strategic consultant since Oct 2024; background includes Novo Nordisk and Radius Health."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161701,"accession_number":"0001437749-25-019471","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity Therapeutics partners with Indiana Biosciences Research Institute to study stenoparib's dual mechanism","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Collaboration aims to clarify contributions of PARP inhibition and WNT pathway modulation to stenoparib's anticancer effects.","Stenoparib is a dual PARP1/2 and tankyrase1/2 inhibitor currently in Phase 2 trial for advanced ovarian cancer.","Research may support future marketing approval and potential expansion into colorectal cancer and SCLC combination trial.","No financial terms of the collaboration were disclosed in the press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161700,"accession_number":"0001437749-25-019219","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity enrolls first patient in Phase 2 stenoparib trial for advanced ovarian cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in new Phase 2 protocol for platinum-resistant or platinum-ineligible advanced ovarian cancer.","Trial includes DRP companion diagnostic to enrich for stenoparib responders.","Two patients remain on prior Phase 2 study on twice-daily dosing, deriving benefit beyond 20 months.","Additional dosing level added aligning with FDA Project Optimus to inform pivotal trial design.","Company expects significant clinical data by late summer 2026; pursuing accelerated regulatory pathways."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161699,"accession_number":"0001437749-25-016264","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity CEO to present company overview at Pharma Partnering Summit US on May 14-15","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Thomas H. Jensen will deliver a company overview on stenoparib (dual PARP/WNT inhibitor) and DRP® platform.","One-on-one meetings will be conducted at the event in San Diego, CA on May 14-15, 2025.","Participation is a standard business development and licensing conference activity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161698,"accession_number":"0001437749-25-015778","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allarity Therapeutics Q1 net loss $2.7M, cash $27.7M; stenoparib shows durable benefit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $2.7M in Q1 2025 from $3.8M in Q1 2024; R&D expenses $1.4M, G&A $1.6M.","Cash and restricted cash $27.7M at March 31, 2025, up from $20.9M at December 31, 2024.","Two ovarian cancer patients on stenoparib >19 months; new Phase 2 protocol for platinum-resistant disease begins H1 2025.","VA-funded Phase 2 trial of stenoparib + temozolomide in SCLC to begin enrollment Q2-Q3 2025.","Authorized $5M share repurchase program; ~2M shares bought; SEC settlement and class action lawsuit resolved."],"consensus_eps_estimate":-0.2244,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161697,"accession_number":"0001437749-25-013236","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity presents novel DRP for daratumumab in multiple myeloma at AACR","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First DRP developed for an antibody therapy (daratumumab), expanding platform beyond small molecules.","DRP identified 53 genes (27 sensitivity, 26 resistance) from in vitro data and KYDAR trial bone marrow samples.","Predictor aims to identify multiple myeloma patients likely to benefit from daratumumab; presented at AACR 2025.","Management highlights potential for future collaborations to bring precision diagnostics to more patients.","Allarity's lead program, stenoparib (dual PARP/WNT inhibitor), remains in Phase 2 for ovarian cancer and small cell lung cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161696,"accession_number":"0001437749-25-012153","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["5.02","5.08"],"status":"ready","headline":"Allarity rebalances board classes, sets June 13 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Thomas H. Jensen resigned from Class I and immediately re-elected as Class III director, term expires 2028.","Board now consists of one Class I, two Class II, and one Class III director.","Annual meeting set for June 13, 2025; record date April 16, 2025.","Deadline for stockholder proposals and director nominations is April 28, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179808,"accession_number":"0001437749-25-010187","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allarity Therapeutics FY2024 net loss $24.5M; cash $20.9M at year-end, ~$25M at Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $24.5M for 2024 vs $11.9M in 2023, driven by $9.7M intangible impairment and $2.5M SEC settlement.","Cash and receivables $20.9M at Dec 31, 2024, and ~$25M at end of Q1 2025; expected to fund operations into 2027.","R&D expenses decreased to $6.1M from $7.1M; G&A expenses $11.4M (including SEC accrual).","Enrollment in Phase 2 ovarian cancer trial expected H1 2025; VA-funded SCLC combination trial enrollment Q2-Q3 2025.","Authorized $5M share repurchase program; ATM program fully utilized and concluded."],"consensus_eps_estimate":-0.2244,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179807,"accession_number":"0001437749-25-009132","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity Therapeutics engages ShareIntel to investigate potential illegal naked short selling","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Engaged Shareholder Intelligence Services (ShareIntel) to probe potential illegal naked short selling and trading irregularities.","Will use ShareIntel's DRIL-Down™ platform to analyze trading data from broker-dealers and clearing firms.","CEO Thomas Jensen cites investor inquiries and notable stock volatility as drivers for the investigation.","If violations of SEC Regulation SHO are found, Allarity will consider legal recourse against responsible parties.","Investigation aims to protect shareholder value as the company advances clinical development of stenoparib."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179806,"accession_number":"0001437749-25-008139","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity reports Phase 2 data for stenoparib in advanced ovarian cancer; durable benefit in platinum-resistant patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["5 of 15 patients stayed on therapy >4 months; 1 had confirmed complete response lasting >10 months.","2 patients remain on therapy >17 months; patient with primary platinum-refractory disease remained >40 weeks.","Stenoparib well-tolerated with no bone marrow toxicity typical of first-generation PARP inhibitors.","Clinical benefit seen in BRCA wild-type patients, supporting dual PARP/Wnt pathway inhibition.","New Phase 2 protocol announced focusing on platinum-resistant patients with single prior chemo line."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179805,"accession_number":"0001437749-25-007620","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity settles SEC probe over FDA disclosures; pays $2.5M civil penalty","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Final settlement with SEC: administrative cease-and-desist order, no admission or denial of findings.","Civil penalty of $2.5 million; cash runway into 2026 unchanged per prior guidance.","Resolves investigation into past disclosures about FDA interactions regarding Dovitinib NDA (2021).","All outstanding legal matters now concluded, including securities class action dismissed Feb 2025.","Company reaffirms focus on stenoparib Phase 2 trials in ovarian and small cell lung cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179804,"accession_number":"0001437749-25-006559","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity announces VA-funded Phase 2 trial of stenoparib + temozolomide in recurrent SCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 trial of stenoparib (dual PARP/Wnt inhibitor) plus temozolomide for recurrent SCLC, fully funded by VA.","Trial expects ~65 patients across 11 VA medical centers; initial safety lead-in to set recommended dose.","Cash position supports operations into 2026; VA funding does not affect financial outlook or share repurchase plan.","Stenoparib crosses blood-brain barrier, potentially treating brain metastases common in SCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179803,"accession_number":"0001437749-25-006012","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity Therapeutics authorizes $5M share repurchase program through Feb 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized repurchase of up to $5M of common stock; program runs through Feb 28, 2026.","CEO Thomas Jensen cites confidence in stenoparib’s clinical potential and long-term vision.","Company says sufficient cash position maintains runway into 2026, unaffected by buyback.","Repurchases discretionary; may be made via open market or other methods under Rule 10b-18.","Allarity is a Phase 2 clinical-stage biotech developing dual PARP/Wnt inhibitor stenoparib."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179802,"accession_number":"0001437749-25-005341","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity Therapeutics announces dismissal of securities class action lawsuit against all defendants","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Securities class action filed Sept 13, 2024, alleging false statements on Dovitinib NDA prospects dismissed with prejudice.","No settlement or payment was made by the Company or officers in connection with dismissal.","CEO Thomas Jensen says dismissal allows focus on Phase 2 trial of stenoparib for advanced ovarian cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179801,"accession_number":"0001437749-25-004971","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity initiates new Phase 2 protocol for stenoparib in advanced ovarian cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Patient enrollment begins at US sites with new drug product delivered for new Phase 2 protocol.","Two patients in ongoing phase 2 remain on stenoparib for over 17 months without progression.","Protocol incorporates FDA feedback and IRB approval; critical data expected by end of summer 2026 for pivotal trial.","Trial will evaluate stenoparib-DRP companion diagnostic alongside drug for dual regulatory submission.","Targets $9B+ PARP inhibitor market and addresses FDA Project Optimus dose-finding guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179800,"accession_number":"0001437749-25-003074","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-02-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity expands Phase 2 trial of stenoparib in advanced ovarian cancer; enrollment targets H1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New Phase 2 protocol focuses on advanced, recurrent, platinum-resistant ovarian cancer patients.","Trial aims to optimize stenoparib dose and refine DRP patient selection criteria for companion diagnostic.","Some patients on stenoparib for over 14 months demonstrate durable clinical benefit.","Enrollment expected to begin first half of 2025, subject to regulatory approval including FDA review.","Stenoparib is a dual PARP/Wnt inhibitor; trial will investigate Wnt pathway impact to differentiate treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179799,"accession_number":"0001437749-25-002184","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Allarity Therapeutics reaches $2.5M SEC settlement over Dovitinib disclosure issues","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Agreed in principle with SEC to pay $2.5M civil penalty and consent to cease-and-desist order for non-scienter securities law violations.","Investigation concerns company's disclosures about FDA meetings for Dovitinib NDA submitted in 2021.","Three former officers received Wells Notices; company has accrued ~$1.8M for their legal fees, with insurance coverage subject to $3.5M retention.","Settlement is subject to final language and SEC approval; company must cooperate in any future SEC litigation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196568,"accession_number":"0001437749-24-035686","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2024-11-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity: Two stenoparib patients exceed 14 months; $18.5M cash; lab services revenue","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two advanced ovarian cancer patients on stenoparib Phase 2 trial beyond 14 months, a notable duration given heavy pretreatment.","Cash balance of $18.5M as of Sept 30, 2024, sufficient to initiate registrational trial toward FDA approval.","Allarity Medical Lab signs external service agreements for DRP and gene expression analysis with multiple biotech firms.","Revenue from lab services reduces overall lab cost base and advances DRP platform in oncology field."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196567,"accession_number":"0001437749-24-035040","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allarity Therapeutics reports Q3 net loss $12.2M; cash $18.5M; Phase 2 stenoparib patients exceed one year on treatment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $12.2M vs $5.6M YoY; includes $9.7M non-cash intangible impairment charge.","Cash and equivalents $18.5M at Sept 30, 2024, up from $0.2M at Dec 31, 2023; runway into 2026.","Phase 2 stenoparib trial: two ovarian cancer patients exceeded one year on treatment.","Appointed Alexander Epshinsky as CFO; Jeremy Graff as President/Chief Development Officer; Jose Iglesias as Consultant CMO.","Regained NASDAQ compliance; European patent granted for stenoparib DRP companion diagnostic."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196566,"accession_number":"0001437749-24-031806","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2024-10-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"European Patent Office intends to grant patent for Allarity's DRP companion diagnostic for stenoparib","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["EPO issued formal notice of intention to grant patent for DRP companion diagnostic for stenoparib, a PARP/Tankyrase inhibitor.","Patent covers use of DRP to identify cancer patients most likely to benefit from stenoparib treatment.","Patent applications for Stenoparib DRP also pending in US, Japan, China, Australia, and India.","Allarity now has 17 granted DRP patents, including 8 in the US, strengthening its intellectual property portfolio.","CEO Thomas Jensen stated the patent is key for securing international market position ahead of potential commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196565,"accession_number":"0001437749-24-031059","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2024-10-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allarity regains Nasdaq minimum bid price compliance after 20-day period","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Oct 9, 2024 confirming compliance with Listing Rule 5550(a)(2).","Stock closing bid price was $1.00 or greater for 20 consecutive days from Sept 11 to Oct 9, 2024.","Non-compliance was first notified on June 18, 2024; this matter is now closed.","CEO Thomas Jensen stated focus remains on stenoparib Phase 2 trial in advanced ovarian cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196564,"accession_number":"0001437749-24-030661","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Allarity Therapeutics appoints Graff President, Iglesias CMO, Høiland Advisor to advance stenoparib","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeremy Graff, Ph.D., named President & CDO; base salary $475K, RSUs $250K, signing bonus $75K.","Jose Iglesias, M.D., appointed Consultant CMO; led Phase III Abraxane development at Celgene.","Jesper Høiland, former President of Novo Nordisk U.S., joins as Strategic Advisor for commercial strategy.","Appointments target accelerating stenoparib, a dual PARP/Tankyrase inhibitor, for advanced ovarian cancer.","Graff previously consulted for Allarity since Dec 2023; brings 25+ years pharma experience including 17 at Eli Lilly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212874,"accession_number":"0001213900-24-079165","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Allarity Therapeutics reports two ovarian cancer patients exceed one year on stenoparib therapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two patients in Phase 2 trial for advanced recurrent ovarian cancer have exceeded one year on stenoparib.","Patients pre-screened using DRP companion diagnostic; show durable clinical benefit in heavily pre-treated population.","One confirmed complete response and long-term disease stability observed.","CEO notes extending life by 52 weeks is noteworthy for heavily pre-treated patients.","Company planning next phase of development, accelerating path toward regulatory approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212873,"accession_number":"0001213900-24-078294","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Allarity Therapeutics CFO resigns; appoints Alexander Epshinsky; boosts ATM capacity to $50M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joan Brown resigned as CFO effective Sept 12, 2024; no disagreement with company.","Alexander Epshinsky appointed CFO effective Sept 12; $340k base salary, $50k signing bonus, $160k RSUs (3-year vest).","ATM sales agreement second amendment increases placement shares capacity to $50 million.","Company states it paused financing but now, with new CFO, will pursue financing opportunities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212868,"accession_number":"0001213900-24-077144","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K/A","filed_at":"2024-09-10T23:59:59+00:00","items":["3.03","5.03","5.02","5.07","9.01"],"status":"ready","headline":"Allarity Therapeutics corrects reverse stock split effective time to Sept 11, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Certificate of Correction filed to set 1-for-30 reverse split effective 12:01 a.m. ET Sept 11, 2024.","Charter amendment reduces authorized shares from 750.5M to 250.5M, effective Sept 9 at 9:30 a.m. ET.","2021 Equity Incentive Plan shares increased from 2,168,330 to 10,594,876 approved at Annual Meeting.","All 7 stockholder proposals passed at Sept 3 Annual Meeting, including director elections and auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212872,"accession_number":"0001213900-24-076728","cik":1860657,"company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["3.03","5.03","5.02","5.07","9.01"],"status":"ready","headline":"Allarity Therapeutics files 1-for-30 reverse stock split, reduces authorized shares to 250M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 1-for-30 reverse split at Sept 3 annual meeting; effective Sept 11, 2024.","Authorized common shares reduced from 750M to 250M via Sixth Certificate of Amendment.","Board also amended 2021 Equity Plan to increase shares reserved from ~2.2M to ~10.6M (pre-split).","Directors Gerald W. McLaughlin and Laura E. Benjamin re-elected to Class II.","Trading symbol ALLR unchanged; no fractional shares, rounding up."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":27048230.289017342,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-09-09T23:59:59+00:00|212872"}